Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 20Ovarian Neoplasms 19Fallopian Tube Neoplasms 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Metastatic Castration-resistant Prostate Cancer 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Glioma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Osteosarcoma 2Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

olaparib 1Pluvicto 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Castration Resistant Prostate Cancer (mCRPC) × olaparib × Clear all
NCT03874884 2025-05-14

LuPARP

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting
70 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡